Study spells bad news for Elan drug

A new US study has found that the risk of a potentially fatal brain disorder increases as patients recieve more infusions of Elan's multiple sclerosis drug Tsyabri.

The drug, which the Irish pharmaceutical firm Elan co-produces with Biogen, was withdrawn from use for a time two years ago after it was first linked to the brain disorder PML.